| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| Cephalothin (153-61-7) | Nephrotoxicity | Antagonistic | Probenecid inhibits the excretion of most cephalosporins by the kidney tubules by successfully competing for the excretory mechanisms. Thus the cephalosporin is retained in the body and its serum levels rise. The extent of the rise cannot always be fully accounted for by this mechanism alone and it is suggested that some change in tissue distribution may sometimes have a part to play. | Probenecid: an unexplained effect on cephalosporin pharmacology
|
| Cephaloridine (50-59-9) | Nephrotoxicity | Antagonistic | Probenecid inhibits the excretion of most cephalosporins by the kidney tubules by successfully competing for the excretory mechanisms. Thus the cephalosporin is retained in the body and its serum levels rise. The extent of the rise cannot always be fully accounted for by this mechanism alone and it is suggested that some change in tissue distribution may sometimes have a part to play. | Probenecid: an unexplained effect on cephalosporin pharmacology
|
| Methotrexate (59-05-2) | Pancytopenia | Synergistic | Probenecid inhibits the renal excretion of methotrexate | Inhibition of renal tubular transport of methotrexate by probenecid
|
| Ketorolac (66635-83-4) | Disorder Gastrointestinal | Antagonistic | Probenecid is a known substrate for renal glucuronidation, and possibly
competitively inhibits the renal glucuronidation of these NSAIDs | Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans A pilot experiment
|
| Pyrazinamide (98-96-4) | Diminished Uricosuric Effects Of Probenecid | Antagonistic | pyrazinamide additionally decreases the metabolism of the probenecid and prolongs its uricosuric effects | Studies of hyperuricemia produced by pyrazinamide
|